Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases

Amritpal Singh, Aref Al-Kali, Kebede H. Begna, Mark R. Litzow, Jeremy T. Larsen, Taimur Sher, Maymona G. Abdelmagid, Faiqa Farrukh, Kaaren K. Reichard, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi

Research output: Contribution to journalArticlepeer-review


We retrospectively examined our experience with midostaurin therapy in 33 consecutive patients (median age 68 years; 58% females) with advanced systemic mastocytosis (adv-SM): aggressive SM (ASM; n = 17), SM associated with another hematologic neoplasm (SM-AHN; n = 14) and mast cell leukemia (MCL; n = 2). KITD816V mutation was detected in 84% of the patients and C findings in 91%. Eleven (33%) patients were previously treated with other cytoreductive drugs, including cladribine (n = 4) and imatinib (n = 3). Median time from diagnosis to initiation of midostaurin therapy was 2.2 months (range 0.3–41). Using modified valent criteria, overall response was 42% (53% ASM, 29% SM-AHN, 50% MCL; p =.22), all classified as being major. Responses included ≥50% reduction in bone marrow mast cells in 40% and normalization of serum tryptase in 29%, of evaluated cases. After a median follow-up of 14.6 months from initiation of midostaurin therapy, 7 (21%) deaths, 1 (3%) leukemic progression, and 18 (55%) treatment discontinuations were documented; median duration of midostaurin treatment was 7.9 months (range 0.5–123) and response duration 21.5 months (range 2.9–123). Most frequent side effect was gastrointestinal (51%) while grade 3/4 neutropenia or thrombocytopenia occurred in 12% of patients. Response to treatment was not predicted by KIT mutation (p =.67) or exposure to prior cytoreductive therapy (p =.44). Median survival was longer in midostaurin responders but not significantly (median 26.5 vs. 16 months; p =.15). Findings from the current study are broadly consistent with previously published clinical trial observations.

Original languageEnglish (US)
Pages (from-to)630-637
Number of pages8
JournalAmerican journal of hematology
Issue number5
StatePublished - May 2022

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases'. Together they form a unique fingerprint.

Cite this